Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Hinova Pharmaceuticals's Revenue for the
three
months ended in Mar. 2026 was ¥26.03 Mil. Hinova Pharmaceuticals's average Accounts Receivable for the
three
months ended in Mar. 2026 was ¥1.54 Mil.
Hence, Hinova Pharmaceuticals's Receivables Turnover for the
three
months ended in Mar. 2026 was 16.88.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Hinova Pharmaceuticals Receivables Turnover Related Terms
Hinova Pharmaceuticals Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Hinova Pharmaceuticals's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688302 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Hinova Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hinova Pharmaceuticals Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Hinova Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hinova Pharmaceuticals (SHSE:688302) has a Receivables Turnover of 16.88 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hinova Pharmaceuticals and its competitors. According to the industry distribution chart, Hinova Pharmaceuticals ranks #115 out of 843 companies in the Biotechnology industry, placing it in the top 13.6%.
Is Hinova Pharmaceuticals' Receivables Turnover too high?
Hinova Pharmaceuticals' current Receivables Turnover is 16.88. The Biotechnology industry median Receivables Turnover is 5.27. Hinova Pharmaceuticals' value of 16.88 is 220.3% above this industry median. Based on the distribution chart, Hinova Pharmaceuticals ranks #115 out of 843 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hinova Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hinova Pharmaceuticals ranks #115 out of 843 companies for Receivables Turnover. This places Hinova Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. Hinova Pharmaceuticals' value of 16.88 is 220.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hinova Pharmaceuticals's current Receivables Turnover of 16.88 is 220.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hinova Pharmaceuticals and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hinova Pharmaceuticals's current Receivables Turnover is 16.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Receivables Turnover of 16.88. The current Receivables Turnover is 16.88 and 220.3% above the Biotechnology industry median of 5.27. Hinova Pharmaceuticals' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Receivables Turnover is 16.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
32GF Score
Get the complete analysis for SHSE:688302
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688302 has been successfully added to your 
